gentulizumab / GeneScience - LARVOL DELTA

Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile. (PubMed, J Transl Med) - "GenSci059 selectively binds to CD47, effectively blocks the CD47/SIRPα axis signaling pathway and enhances the phagocytosis effects of macrophages toward tumor cells. This monoclonal antibody demonstrates potent antitumor activity and exhibits a favorable safety profile, positioning it as a promising and effective therapeutic option for cancer."

Journal • Hematological Disorders • Hematological Malignancies • Oncology • SIRPA

Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=58 | Terminated | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Trial completion date: May 2024 ➔ Oct 2023 | Recruiting ➔ Terminated | Trial primary completion date: May 2024 ➔ May 2023; Due to changes in the sponsor's research strategy

Metastases • Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: GeneScience Pharmaceuticals Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology